Related Experiment Videos
Cortical blindness and seizures in a patient receiving FK506 after bone marrow transplantation
R E Steg1, A Kessinger, Z K Wszolek
1Department of Neurology, Creighton University School of Medicine, Omaha, NE 68131-2197, USA.
Bone Marrow Transplantation
|May 25, 1999
Abstract:
A 54-year-old woman with a myelodysplastic syndrome treated with high-dose chemotherapy and an allogenic bone marrow transplant developed acute cortical blindness while receiving tacrolimus (FK506). MRI showed white matter abnormalities. After discontinuation of FK506, the patient's vision returned within 8 days. FK506 neurotoxicity is similar to cyclosporine neurotoxicity and can occur in allogenic bone marrow transplant patients treated with FK506.